These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15676296)

  • 21. Lead optimization via high-throughput molecular docking.
    Joseph-McCarthy D; Baber JC; Feyfant E; Thompson DC; Humblet C
    Curr Opin Drug Discov Devel; 2007 May; 10(3):264-74. PubMed ID: 17554852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anticalins: the lipocalin family as a novel protein scaffold for the development of next-generation immunotherapies.
    Hohlbaum AM; Skerra A
    Expert Rev Clin Immunol; 2007 Jul; 3(4):491-501. PubMed ID: 20477155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Binding proteins from alternative scaffolds.
    Nygren PA; Skerra A
    J Immunol Methods; 2004 Jul; 290(1-2):3-28. PubMed ID: 15261569
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rational approaches to natural-product-based drug design.
    Haustedt LO; Mang C; Siems K; Schiewe H
    Curr Opin Drug Discov Devel; 2006 Jul; 9(4):445-62. PubMed ID: 16889228
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural genomics and drug discovery: all in the family.
    Weigelt J; McBroom-Cerajewski LD; Schapira M; Zhao Y; Arrowsmith CH
    Curr Opin Chem Biol; 2008 Feb; 12(1):32-9. PubMed ID: 18282486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physics-based methods for studying protein-ligand interactions.
    Huang N; Jacobson MP
    Curr Opin Drug Discov Devel; 2007 May; 10(3):325-31. PubMed ID: 17554859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 12-O-retinoylphorbol-13-acetate (RPA) behaves like a retinoid-derivative in binding to retinol-binding-protein: a correlation with its specific action as an incomplete tumor promoter?
    Schlatterer K; Gminski R; Schlatterer J; Hecker E; Chandra P; Schlatterer B; Krauter G; Chandra A
    Anticancer Res; 2005; 25(5):3355-65. PubMed ID: 16101150
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Engineered protein scaffolds as next-generation antibody therapeutics.
    Gebauer M; Skerra A
    Curr Opin Chem Biol; 2009 Jun; 13(3):245-55. PubMed ID: 19501012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Compact packing of lipocalin-type prostaglandin D synthase induced by binding of lipophilic ligands.
    Inoue K; Yagi N; Urade Y; Inui T
    J Biochem; 2009 Feb; 145(2):169-75. PubMed ID: 19015161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The retinol-binding protein system: a potential paradigm for steroid-binding globulins?
    Redondo C; Burke BJ; Findlay JB
    Horm Metab Res; 2006 Apr; 38(4):269-78. PubMed ID: 16700009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alternative binding proteins: biological activity and therapeutic potential of cystine-knot miniproteins.
    Kolmar H
    FEBS J; 2008 Jun; 275(11):2684-90. PubMed ID: 18435757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new generation of protein display scaffolds for molecular recognition.
    Hosse RJ; Rothe A; Power BE
    Protein Sci; 2006 Jan; 15(1):14-27. PubMed ID: 16373474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peptide aptamers as guides for small-molecule drug discovery.
    Baines IC; Colas P
    Drug Discov Today; 2006 Apr; 11(7-8):334-41. PubMed ID: 16580975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alternative drug discovery approaches for orphan GPCRs.
    Levoye A; Jockers R
    Drug Discov Today; 2008 Jan; 13(1-2):52-8. PubMed ID: 18190864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biochemical basis for retinol deficiency induced by the I41N and G75D mutations in human plasma retinol-binding protein.
    Folli C; Viglione S; Busconi M; Berni R
    Biochem Biophys Res Commun; 2005 Nov; 336(4):1017-22. PubMed ID: 16157297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug discovery and natural products: end of an era or an endless frontier?
    Li JW; Vederas JC
    Science; 2009 Jul; 325(5937):161-5. PubMed ID: 19589993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular modeling of hydration in drug design.
    Mancera RL
    Curr Opin Drug Discov Devel; 2007 May; 10(3):275-80. PubMed ID: 17554853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Informatics and modeling challenges in fragment-based drug discovery.
    Hubbard RE; Chen I; Davis B
    Curr Opin Drug Discov Devel; 2007 May; 10(3):289-97. PubMed ID: 17554855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Designing peptide receptor agonists and antagonists.
    Hruby VJ
    Nat Rev Drug Discov; 2002 Nov; 1(11):847-58. PubMed ID: 12415245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rational engineering of a fluorescein-binding anticalin for improved ligand affinity.
    Vopel S; Mühlbach H; Skerra A
    Biol Chem; 2005 Nov; 386(11):1097-104. PubMed ID: 16307475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.